Compare COST & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COST | AZN |
|---|---|---|
| Founded | 1976 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.2B | 285.7B |
| IPO Year | 1994 | N/A |
| Metric | COST | AZN |
|---|---|---|
| Price | $1,010.12 | $201.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 1 |
| Target Price | ★ $1,015.95 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | 0.52% | ★ 1.57% |
| EPS Growth | ★ 9.96 | N/A |
| EPS | ★ 4.50 | N/A |
| Revenue | ★ $275,235,000,000.00 | N/A |
| Revenue This Year | $10.05 | $9.84 |
| Revenue Next Year | $7.42 | $6.16 |
| P/E Ratio | $223.38 | ★ $31.91 |
| Revenue Growth | ★ 8.17 | N/A |
| 52 Week Low | $844.06 | $61.24 |
| 52 Week High | $1,067.08 | $212.71 |
| Indicator | COST | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 69.90 |
| Support Level | $1,002.00 | $89.28 |
| Resistance Level | $1,033.95 | $212.71 |
| Average True Range (ATR) | 18.85 | 3.45 |
| MACD | -1.48 | -3.72 |
| Stochastic Oscillator | 68.66 | 25.05 |
Founded in 1983, Costco Wholesale now operates a global chain of membership-based warehouse clubs, delivering high-quality goods and services at consistently low prices. As of its most recent fiscal year, Costco operated approximately 910 warehouses, serving more than 80 million members across its three geographic segments: Costco US (approximately 73% of total revenue), Costco Canada (13%), and Costco International (14%).Costco's core value proposition—quality products at unbeatable prices—has yielded consistently strong member renewal rates (93% in the US and Canada and nearly 90% internationally). About 55% of Costco's fiscal 2025 revenue came from its grocery offerings, and another 25% from general merchandise.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.